Skip to main content

Table 1 Characteristics of included studies

From: The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials

Study Intervention No.of participants Age,years
Median (range)
Type of trial Patient characteristics Pretreatment status Main outcomes   
Pujade-Lauraine 2010 [13] carbo(AUC5) + PLD 30 mg/m2 q4wks 466 60.5 (24–82) phase III randomized multicenter, open-label trial PS ROC After first-or second-line
Platinum and taxane-based
PFS, OS,
Toxicity
  
carbo(AUC5) + PAC 175 mg/m2 q3wks 509 61 (27–82)   
Gladieff2012 [14] carbo(AUC5) + PLD 30 mg/m2 q4wks 161 60 (24–82) phase III randomized non-inferiority trial PS ROC After first- or second-line platinum- and taxane-based PFS,
Toxicity
  
carbo(AUC5) + PAC 175 mg/m2 q3wks 183 60 (30–80)    
Mahner2014 [15] carbo(AUC5) + PLD 30 mg/m2 q4wks 131 60 (30–80) phase III randomized multicenter trial PS ROC Platinum and
taxane-pretreated
PFS, OS,
Toxicity
  
carbo(AUC5) + PAC 175 mg/m2 q3wks 128 63 (27–82)   
Bafaloukos2010 [16] carbo(AUC5) + PLD 45 mg/m2 q4wks 93 62 (38–89) phase II randomized
multicenter
PS ROC One cycle or more
Of platinum-based
ORR, OS,
Toxicity
  
carbo(AUC5) + PAC 175 mg/m2 q3wks 96 63 (37–81)   
Mutch2007 [17] PLD 50 mg/m2 IVI q4wks 96 62 (28–83) phase III randomized multicenter open-label PS ROC Prior platinum-based
≤ 2 prior regimens allowed
PFS, OS,
Toxicity
  
Gemcitabine 1000 mg/m2 D1,8 q3wks 99 59 (38–85)   
Ferrandina2008 [18] PLD 40 mg/m2 IVI q4wks 76 63 (28–80) phase III randomized
multicenter
Partial PS and
PR ROC
Failed first-line
Platinum or paclitaxel
OS,
Toxicity
  
Gemcitabine 1000 mg/m2 D1,5,8,15 q4wks 77 63 (39–79)   
Vergote2009I [19] PLD 50 mg/m2 IVI q4wks 130 60 (30–82) phase III randomized multicenter platinum-refractory or PR ROC Failed one second-Line therapy with either topotecan or PLD Toxicity   
Canfosfamide 1000 mg/m2 q3wks 231 60 (26–85)   
Vergote2009II [19] PLD 50 mg/m2 IVI q4wks 130 60 (30–82) phase III randomized
multicenter
platinum-refractory or PR ROC Failed one second-Line therapy with either topotecan or PLD Toxicity   
Topotecan 1.5 mg/m2 D1–5 q3wks 87 60 (30–82)   
Colombo2012 [20] PLD 50 mg/m2 IVI q4wks 417 59 (23–84) phase III randomized
open-label
PR ROC Failed≥4 cycles of platinum-based or discontinued PFS, OS,
Toxicity
  
Patupilone 10 mg/m2 IVI q3wks 412 59 (25–87)   
Banerjee2018 [21] PLD 40 mg/m2 IVI q4wks 48 62 (52–86) phase II randomized
open-label
PR ROC Progressed or relapsed < 6 months with a platinum-based PFS,
Toxicity
  
LIFA 2.4 mg/kg q3wks 47 62 (43–83)   
Kaye2012I [22] PLD 50 mg/m2 IVI q4wks 33 53 (43–81) phase II open-label randomized Multicenter Partial PS and PR ROC Recurred or progressed < 12
months with platinum-based
PFS, OS,
Toxicity
  
Olaparib 200 mg bid continuously 32 58.5 (45–77)   
Kaye2012II [22] PLD 50 mg/m2 IVI q4wks 33 53 (43–81) phase II open-label randomized Multicenter Partial PS and
PR ROC
Recurred or progressed < 12
months with platinum-based
PFS,OS,
Toxicity
  
Olaparib 400 mg bid continuously 32 53.5 (35–76)   
  1. Note: OS Overall survival; PFS Progression-free survival; PS Platinum-sensitive; PR Platinum-resistant; ROC Recurrent ovarian cancer